Superbugs could kill millions more and cost $2tn a year by 2050, study shows
A British government-funded study shows that without concerted action, increased rates of antimicrobial resistance (AMR) could lead to global annual GDP losses of $1.7tn over the next quarter of a century.
The research, by the Center for Global Development thinktank, found the US, British and EU economies would be among the hardest hit, prompting accusations that recent swingeing aid cuts are self-defeating.
The Trump administration has confirmed $9bn in cuts to its foreign aid budget, while a number of European countries have also reduced spending on overseas aid.
Anthony McDonnell, the lead author of the research and a policy fellow at the Center for Global Development, said: 'When we conducted our research on the economic impacts of antimicrobial resistance, it was anticipated that resistance rates would continue to follow historical trends.
'However, the sudden cuts to Official Development Assistance by the US, which has cut its aid spend by roughly 80%; the UK, which has announced aid cuts from 0.5% to 0.3% of gross national income; and substantial reductions by France, Germany, and others, could drive up resistance rates in line with the most pessimistic scenario in our research.
'Even countries that have been successful in keeping AMR rates under control cannot afford to be complacent. Unless AMR programmes are protected from aid cuts, resistance rates across the world will likely increase at a rate in line with the worst-affected countries.
This would result in millions more people dying worldwide, including across G7 nations. Investing in treatment for bacterial infections now will save lives and deliver billions in long-term economic returns.
The research calculated the economic and health burden of antibiotic resistance for 122 countries and forecast that in this most pessimistic scenario, by 2050, GDP losses in China could reach just under $722bn a year, the US $295.7bn, the EU $187bn, Japan $65.7bn and Britain $58.6bn.
According to the Institute for Health Metrics and Evaluation (IHME), deaths from AMR are expected to increase 60% by 2050, with 1.34 million people in the US and 184,000 in Britain alone predicted to die each year from antibiotic-resistant bugs, while numbers of those becoming seriously ill from drug-resistant bacteria are also expected to jump.
Superbugs increase the number of hospital admissions and lead to longer and more intensive hospital stays, costlier second-line treatments and more complex care, meaning resistant infections are roughly twice as expensive to treat as those for which antibiotics are effective.
The study estimates global health costs of treating AMR could increase by just under $176bn a year.
Higher rates of resistant bugs would also shrink the British, EU and US workforces by 0.8%, 0.6% and 0.4% respectively, the study found.
The Guardian
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RTÉ News
a day ago
- RTÉ News
Israel will let foreign countries drop aid into Gaza, Israel army radio says
Israel will allow foreign countries to parachute aid into Gaza from today, Israeli army radio has said, quoting a military official. An Israeli military spokesperson did not immediately reply to a Reuters request for comment on the report. The Gaza health ministry has said more than 100 people have died from starvation in the Palestinian enclave since Israel cut off supplies to the territory in March. Israel lifted that blockade in May but has restrictions in place that it says are needed to prevent aid from being diverted to militant groups. In the first two weeks of July, the UN children's agency UNICEF treated 5,000 children facing acute malnutrition in Gaza. World Health Organization chief Tedros Adhanom Ghebreyesus said on Wednesday that Gaza was suffering man-made mass starvation caused by a blockade on aid into the enclave. Aid groups have warned of surging numbers of malnourished children in war-ravaged Gaza as a trio of European powers prepared to hold an "emergency call" on the deepening humanitarian crisis. Doctors Without Borders (MSF) said that a quarter of the young children and pregnant or breastfeeding mothers it had screened at its clinics last week were malnourished, a day after the United Nations said one-in-five children in Gaza city were suffering from malnutrition. With fears of mass starvation growing, Britain, France and Germany were set to hold an emergency call to push for a ceasefire between Israel and Hamas and discuss steps towards Palestinian statehood. "I will hold an emergency call with E3 partners tomorrow, where we will discuss what we can do urgently to stop the killing and get people the food they desperately need while pulling together all the steps necessary to build a lasting peace," British Prime Minister Keir Starmer said. The call comes after hopes of a new ceasefire in Gaza faded yesterday when Israel and the United States quit indirect negotiations with Hamas in Qatar. US envoy Steve Witkoff accused the Palestinian militant group of not "acting in good faith". More than 100 aid and human rights groups warned this week that "mass starvation" was spreading in Gaza. Israel has rejected accusations it is responsible for the deepening crisis, which the World Health Organization has called "man-made". Israel placed Gaza under an aid blockade in March, which it only partially eased two months later. The trickle of aid since then has been controlled by the Israeli and US-backed Gaza Humanitarian Foundation, replacing the longstanding UN-led distribution system. Aid groups have refused to work with the GHF, accusing it of aiding Israeli military goals. The GHF system, in which Gazans have to travel long distances and join huge queues to reach one of four sites, has often proved deadly, with the UN saying that more than 750 Palestinian aid-seekers have been killed by Israeli forces near GHF centres since late May. An AFP photographer saw bloodied patients, wounded while attempting to get humanitarian aid, being treated on the floor of Nasser hospital in the southern city of Khan Yunis yesterday. Israel has refused to return to the UN-led system, saying that it allowed Hamas to hijack aid for its own benefit. Accusing Israel of the "weaponisation of food", MSF said that: "Across screenings of children aged six months to five years old and pregnant and breastfeeding women, at MSF facilities last week, 25% were malnourished." It said malnutrition cases had quadrupled since 18 May at its Gaza city clinic and that the facility was enrolling 25 new malnourished patients every day. Israel's military campaign in Gaza has killed 59,587 Palestinians, mostly civilians, according to the health ministry in the Hamas-run territory. Hamas's October 2023 attack that triggered the war resulted in the deaths of 1,219 people, most of them civilians, according to an AFP tally based on official figures. Of the 251 hostages taken during the attack, 49 are still being held in Gaza, including 27 the Israeli military says are dead.
RTÉ News
a day ago
- RTÉ News
'I saw just terrible, terrible injuries'
British Surgeon Professor Nick Maynard who recently returned from Gaza where he spent four weeks working inside Nasser Hospital in the South of the Strip.
RTÉ News
2 days ago
- RTÉ News
Parents call on HSE to make breakthrough peanut allergy treatment available
Parents of children with severe peanut allergies are calling on the HSE to make a breakthrough treatment available in Ireland. Palforzia is a medicine for treating peanut allergy in children from one to 17 years of age. It has been authorised for use in the EU by the European Medicines Agency, but currently there is no planned timeline to roll it out in Ireland. It works by gradually exposing children to higher doses of peanut to help lower the risk of severe reactions, including anaphylaxis. This method is called oral immunotherapy. There are more than 20,000 children in Ireland living with a severe peanut allergy. The current approach is to avoid peanuts in the diet and carry emergency medication in case they are eaten. Some parents are now taking their children, at their own expense, to the UK, US or other European countries to access the Palforzia treatment. Catherine Dolan, from Greystones in Co Wicklow, is among a group of parents who want the HSE to make Palforzia available here. Her six-year-old son has a severe peanut allergy that puts him at risk of anaphylaxis. Ms Dolan said it creates a great deal of anxiety as the family navigates daily interactions. She has considered accessing the treatment abroad but said the logistics are difficult. "We've always had healthcare in our own country, and it does pose a risk when you go outside of the Irish system. I would consider it, we are talking about it, but I'd be really, really cautious about it," she said. Ms Dolan said she feels it is unacceptable that the treatment is available under the NHS in the UK, and other European countries, but not here. "We need to know when, and why. It has to happen. I'm balanced in my view - I know the healthcare system is really stretched, but I know the consultants are there, the care is there, and the expertise is there. We just need a national plan now to roll it out," she said. The HSE said it makes decisions on which medicines are reimbursed by the taxpayer on "objective, scientific and economic grounds". In November 2023, the National Centre for Pharmacoeconomics made a recommendation to the HSE that Palforzia "not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments". Professor of Paediatrics and Child Health in the Royal College of Surgeons in Ireland and Children's Health Ireland Dr Jonathan Hourihane said cost-effectiveness of medicines is usually calculated based on whether the amount of money needed to treat a condition can be recouped through demonstrated savings based on hospital bed use or emergency departments attendances. Dr Hourihane said this metric does not apply to peanut allergy. "This condition is a community-based disease characterised by anxiety and isolation, not by having to go to a hospital every two weeks. So, it's been unreasonably rejected. I think it's disappointing for us as a country, as a country that recruited children to get the licence for the product. And I think it's insulting to the families who have this condition," he said. Dr Hourihane said he attends international conferences and is told by allergy doctors that they are treating Irish children in the US, France, Italy and the UK, among others. He believes it is "a sign of desperation" that parents are willing to travel at their own expense for "care that they should be able to get locally". He added that Irish doctors are not supporting people to access treatment abroad because they are not involved in those programmes and cannot stand over them. Dr Hourihane said: "We are aware of children who've had to attend the emergency hospitals in Dublin having had allergic reactions during their treatment courses, and we don't know what they've reacted to because we're not involved. "So, I think it's putting doctors in allergy clinics in Ireland in a difficult position. They're having to treat children who are having complications of treatment being supervised remotely." Dr Hourihane believes the true impact of peanut allergies has been disregarded. He said: "It's not a trivial illness if you think your child might die tomorrow while you're at work. I think a fundamental problem with the way it's been evaluated is the impact hasn't been fully accepted in the way that families want it to be accepted. "As a clinician I find it frustrating and disappointing that the state-of-the-art treatments that we helped develop internationally [are not available here], and Ireland is a major international player in this area. We're now the laughing stock of the international allergy community." The HSE said the company that has applied to make Palforzia available through the HSE in Ireland has now paused the application until the end of this year. The HSE added that it "is committed to providing access to as many medicines as possible, in as timely a fashion as possible, from the resources available (provided) to it". "The HSE robustly assesses applications for pricing and reimbursement to make sure that it can stretch available resources as far as possible and to deliver the best value in relation to each medicine and ultimately more medicines to Irish citizens and patients," it said.
